Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | ETV6 | P41212 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14863462 | 0.85 | MAPK1 (0.55) | MAPK1LRRK2 | |
| SCHEMBL16291861 | 0.81 | TTK (0.60) | KDRETV6MAPK1LRRK2NTRK1 | |
| SCHEMBL31172415 | 0.80 | FLT3 (0.53) | — | |
| SCHEMBL29602504 | 0.79 | LRRK2 (0.68) | KDRETV6MAPK1LRRK2NTRK1 | |
| SCHEMBL28562784 | 0.79 | TDO2 (0.73) | PIK3CA | |
| SCHEMBL16025858 | 0.76 | LRRK2 (0.70) | PIK3CALRRK2 | |
| SCHEMBL63778 | 0.76 | ALDH1A1 (0.73) | PIK3CA | |
| SCHEMBL14098982 | 0.76 | LRRK2 (0.55) | KDRETV6MAPK1LRRK2 | |
| SCHEMBL4222794 | 0.76 | LRRK2 (0.51) | KDRETV6MAPK1LRRK2 | |
| SCHEMBL31172470 | 0.75 | FLT3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | KDR 2899/4885ETV6 3124/4885MAPK1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.